Overview

A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

Status:
COMPLETED

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.

Phase:

PHASE1

Details

Lead Sponsor:

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Treatments:

Digoxin
Midazolam
repaglinide
Rosuvastatin Calcium